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Research
Inorganic arsenic (iAs) compounds are con­
sidered known human carcinogens that tar­
get multiple sites, including the lung, skin, 
and urinary bladder [International Agency for 
Research on Cancer (IARC) 2004; Pershagen 
1981; Smith et al. 1992; Smith and Steinmaus 
2009; Straif et al. 2009]. In addition, chronic 
exposure to high levels of iAs has been associ­
ated with the development of multiple dis­
eases and deleterious health effects in humans 
(Abernathy et al. 1999; Kapaj et al. 2006).
In humans, as in many animal species, iAs 
is metabolized to mono  methyl  arsonous acid 
(MMA) and dimethyl  arsonic acid (DMA). 
The most cited conceptual model of arsenic 
methylation involves the reduction of penta­
valent iAs (iAsV) to trivalent iAs (iAsIII), with 
subsequent methylation (Drobna et al. 2009). 
The general scheme is as follows:
iAsVO4
3− + 2e → iAsIIIO3
3− + CH3
+  
  → MMAVO3
2− + 2e  
  → MMAIIIO2
2− + CH3
+  
  → DMAVO2
− + 2e  
  → DMAIIIO−
Among these metabolites, MMAIII is the 
most toxic arsenic species (Drobná et al. 2005; 
Ferrario et al. 2008; Kligerman et al. 2003; 
Petrick et al. 2001). It is generally accepted 
that arsenic (+3 oxidation state) methyltrans­
ferase (AS3MT) is responsible for catalyz­
ing methyl group transfer from S­adenosyl 
methio  nine (SAM) to iAs (Thomas et al. 
2007). However, a recent study by Drobna 
et al. (2009) showed that knockout of As3mt 
in the mouse does not completely abolish the 
methylation of iAs, suggesting that there are 
alternative pathways for arsenic methylation in 
these animals. Although Bentley and Chasteen 
(2002) and Hall et al. (1997) suggested that 
arsenic methylation could be due to gastro­
intestinal tract microbiota, they also specu­
lated that unidentified methyl  transferses may 
be responsible for the methylated arsenicals 
found in As3mt­knockout mice. 
We conducted a genome  wide, parallel 
phenotypic screen of yeast deletion mutants 
to identify the genes required for the growth 
of yeast in the presence of MMAIII and iAsIII 
(Jo et al. 2009). We found a yeast strain 
with deletion of MTQ2, which was highly 
resistant to iAsIII. MTQ2 encodes a SAM­
dependent methyltransferase and has been 
shown to be involved in the methylation of 
release factor eRF1 in yeast (Polevoda et al. 
2006). The human ortholog of the yeast 
MTQ2 is N­6 adenine­specific DNA methyl­
transferase 1 (N6AMT1), a putative methyl­
transferase. Although the bacterial homologs 
of N6AMT1 have been shown to methylate 
DNA N6­adenine (Stephens et al. 1996), the 
current data do not indicate its function in 
the methylation of adenine in the DNA of 
mammalian cells (Ratel et al. 2006).
Our goal in the present study was to 
explore the mechanism by which N6AMT1 
confers resistance to arsenic toxicity. We 
enhanced N6AMT1 gene expression in 
UROtsa cells, given its relatively low expres­
sion in these cells. The UROtsa cell line, 
originally isolated from a primary culture 
of normal human uro  epithelium, does not 
methylate arsenic because of the absence 
of AS3MT expression (Drobná et al. 2005; 
Styblo et al. 2000) and has been used as a 
model for bladder epithelium and arsenic­
induced bladder cancer (Bredfeldt et al. 2006; 
Eblin et al. 2008; Sens et al. 2004). Here, 
we show that N6AMT1 is a human methyl­
transferase specifically involved in the bio­
methylation of MMAIII to DMA. Given that 
MMAIII is the most toxic arsenical and its 
implication in arsenic toxicity and carcino­
genicity, N6AMT1 may have a significant 
role in modulating arsenic­induced toxicity 
and carcinogenicity.
Materials and Methods
Cultures of yeast strains and human UROtsa 
cells. The wild­type BY4743 yeast strain was 
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Ba c k g r o u n d: In humans, inorganic arsenic (iAs) is metabolized to methylated arsenical species in 
a multi  step process mainly mediated by arsenic (+3 oxidation state) methyltransferase (AS3MT). 
Among these metabolites is monomethylarsonous acid (MMAIII), the most toxic arsenic species. A 
recent study in As3mt-knockout mice suggests that unidentified methyltransferases could be involved 
in alternative iAs methylation pathways. We found that yeast deletion mutants lacking MTQ2 were 
highly resistant to iAs exposure. The human ortholog of the yeast MTQ2 is N-6 adenine-specific 
DNA methyltransferase 1 (N6AMT1), encoding a putative methyltransferase.
oB j e c t i v e: We investigated the potential role of N6AMT1 in arsenic-induced toxicity. 
Me t h o d s : We measured and compared the cytotoxicity induced by arsenicals and their metabolic 
profiles using inductively coupled plasma–mass spectrometry in UROtsa human urothelial cells with 
enhanced N6AMT1 expression and UROtsa vector control cells treated with different concentra-
tions of either iAsIII or MMAIII. 
re s u l t s: N6AMT1 was able to convert MMAIII to the less toxic dimethyl  arsonic acid (DMA) when 
over  expressed in UROtsa cells. The enhanced expression of N6AMT1 in UROtsa cells decreased 
cyto  toxicity of both iAsIII and MMAIII. Moreover, N6AMT1 is expressed in many human tissues at 
variable levels, although at levels lower than those of AS3MT, supporting a potential participation 
in arsenic metabolism in vivo.
co n c l u s i o n s: Considering that MMAIII is the most toxic arsenical, our data suggest that N6AMT1 
has a significant role in determining susceptibility to arsenic toxicity and carcinogenicity because of 
its specific activity in methylating MMAIII to DMA and other unknown mechanisms.
key w o r d s : arsenic methylation, arsenic toxicity, arsenite, monomethylarsonous acid, N6AMT1. 
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purchased from Invitrogen (Carlsbad, CA), 
and the MTQ2 deletion strain has the same 
background as the wild­type strain. Growth 
was conducted in rich media [yeast extract­
peptone­dextrose (YPD)] at 30°C with shaking 
at 200 rpm. UROtsa cells (generously pro­
vided by P. Simeonova, National Institute for 
Occupational Safety and Health, Morgantown, 
WV) were cultured at a starting cell den­
sity of 4–5 × 104 cells/mL in RPMI 1640 
(Mediatech, Inc., Manassas, VA) with l­glu­
tamine, 10% fetal bovine serum, 100 IU/mL   
penicillin, and 100 μg/mL strepto  mycin 
(Omega Scientific, San Diego, CA), under 
standard culturing conditions.
Arsenical exposures. We purchased 
sodium arsenite [NaAsO2 (iAsIII); purity 
> 99%] from Sigma­Aldrich (St. Louis, 
MO). Diiodomethylarsine [MMAIII iodide 
(MMAIII)] was a generous gift from J. Gandolfi 
(University of Arizona, Tucson, AZ). iAsIII and 
MMAIII solutions were freshly prepared using 
sterile water (Milli­Q; Millipore, Billerica, MA) 
and protected from light before use. Yeast cells 
were treated with either iAsIII or MMAIII at 
concentrations ranging from 0 to 300 μM.
Once UROtsa cells reached 70–80% conflu­
ence in culture, they were treated with iAsIII at 
concentrations from 0 to 100 μM or MMAIII 
at 0–5 μM. 
Yeast growth assay. Yeast strains were 
pre  grown in YPD media to mid­log phase, 
diluted in fresh media to an optical density at 
595 nm (OD595) of 0.0165, and inoculated 
into a 48­well microplate. Stock solutions of 
arsenicals were added to each culture with at 
least three replicate wells per dose.
Plates were incubated in a Tecan GENios 
spectrophotometer (Tecan Systems Inc., San 
Jose, CA) set to 30°C with intermittent shak­
ing, and OD595 measurements were taken at 
15­min intervals for 24 hr. Raw absorbance 
data were averaged for all replicates, corrected 
for background, and plotted as a function of 
time. The area under the curve (AUC) was cal­
culated for the cultures in each well using Prism 
software (version 5.01; GraphPad Software, 
Inc., La Jolla, CA), and the treatments were 
averaged and expressed as a percentage of the 
control.
Human tissue array and real-time quanti-
tative polymerase chain reaction (PCR) assay. 
We used TaqMan­based real­time quanti­
tative polymerase chain reaction (rt­qPCR) 
to quantify N6AMT1 and AS3MT expres­
sion on a panel of 48 normal human tissues 
using the Human Rapid­Scan Plate (OriGene 
Technologies, Inc., Rockville, MD). The 
human tissues were selected from multiple 
individuals of different ethnicity and pooled 
together. We obtained the primers and probes 
used for amplification of N6AMT1, AS3MT, 
and ACTB (β­actin; control) from Applied 
Biosystems (Foster City, CA). Gene expression 
of N6AMT1 and AS3MT was calculated rela­
tive to ACTB using the ΔΔCT method.
N6AMT1 gene expression vector con-
structs and stable cell lines. Human N6AMT1 
cDNA (GenBank accession no. NM_013240; 
National Center for Biotechnology Information 
2011) was PCR amplified with primers   
5´­AACGCAGCGAAGGACTAT­3´ and 
5´­CAGTAGTTCTGGGCACAC­3´. The 
PCR product was gel purified (Qiagen, 
Valencia, CA) and cloned into pcDNA 2.1 
vector (Invitrogen) according to the manu­
facturer’s instructions, and the sequence was 
confirmed. The pcDNA 2.1 vector containing 
the N6AMT1 gene was excised using NotI/
BamHI restriction enzymes (New England 
Biolabs, Ipswich, MA) and subjected to gel 
purification. The nucleo  tides of the N6AMT1 
gene containing BamHI and NotI overhangs 
were annealed and ligated to a linearized 
pRetro X­IRES­ZsGreen vector (Clonetech, 
Mountain View, CA) digested with BamHI 
and NotI (New England Biolabs). The pRetro 
X­IRES­ZsGreen vector is a fluorescent retro­
viral expression vector that allows both a 
gene of interest and the ZsGreen gene to be 
expressed. The resultant constructs were ampli­
fied, purified, and sequenced. UROtsa cells 
were transfected with this constructed vector 
or a control vector using Lipofectamine 2000 
reagent (Invitrogen) according to the manufac­
turer’s instructions. After incubation at 37°C 
for 8 hr, the super  natant fraction containing 
the retro  viral vector was removed and replaced 
with normal growth medium. Cells grown 
for 48–72 hr were assessed by fluorescence 
microscopy. The ZsGreen fluorescent marker 
yields a bright green fluorescence, permitting 
direct monitoring of the delivery efficiency. 
Finally, the cell populations were sorted by 
the DAKO­Cytomation MoFlo High Speed 
Sorter (Dako North America, Carpinteria, 
CA), and the green fluorescent cells were puri­
fied and collected for continuing culture. The 
green fluorescent cells were used for additional 
experimentation.
Semiquantitative reverse-transcrip-
tion (RT)-PCR. UROtsa cells with either 
N6AMT1 or plasmid vectors were col­
lected, and total RNA was isolated from 
these cells using the Qiagen RNAEasy 
Mini kit. We performed a reverse transcrip­
tion reaction using SuperScript II Reverse 
Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. The PCR con­
ditions for DNA amplification in the linear 
range were established on the GeneAmp 
PCR System 7600 (PerkinElmer, Inc., 
Wellesley, MA). The primers for DNA 
amplification were as follows: N6AMT1, 
5´­AACGCAGCGAAGGACTAT­3´ and 
5´­CAGTAGTTCTGGGCACAC­3´; 
AS3MT, 5´­GTGTCTGGGTG  GTGCTT 
TATA  CTG­3´ and 5´­TGGAGGGCAGA 
ACCCAATT­3´; and the housekeeping 
gene ACTB, 5­TCACC  CACACTGTGC 
CCATCTACGA­3 and 5­CAGCGGAAC 
CGCTCAT  TGCCAATGG­3. RT­PCR 
products were analyzed on 1% agarose gels.
Cytotoxicity assay. We performed the 
3­(4,5­dimethyl  thiazol­2­yl)­2,5­diphenyl­2H­
tetrazolium bromide (MTT) assay to assess cell 
viability after arsenic treatment. Cells were cul­
tured in 96­well plates in a volume of 100 μL 
medium/well at a density of 5 × 104 cells/mL. 
Twenty­four hours after incubation with iAsIII 
or MMAIII (six replicates/arsenical concentra­
tion), 10 μL sterile MTT dye (Sigma­Aldrich; 
5 mg/mL) was added to each well and plates 
were incubated at 37°C for 4 hr. The culture 
medium was then removed, and 200 μL dime­
thyl sulfoxide was added and thoroughly mixed 
for 10 min. Spectrophotometric absorbance at 
570 nm was measured in a microplate reader.
Arsenic species profile analysis by high-
performance liquid chromatography/induc-
tively coupled plasma–mass spectrometry 
(HPLC-ICP-MS) methods. UROtsa cells with 
N6AMT1 and UROtsa cells with vector were 
grown in RPMI 1640 medium supplemented 
with 10% fetal bovine serum and anti  biotics. 
Culture medium was collected after exposure to 
iAsIII or MMAIII for 24 hr or 3 days and stored 
at –80°C until analysis. Cells treated with iAsIII 
or MMAIII for 3 days were collected, lysed in 
RIPA buffer, and extracted in methanol by 
incubating overnight at 4°C in a rotational 
shaker. After centrifugation at maximum speed 
for 5 min at 4°C, supernatants were transferred 
to micro  centrifuge tubes and stored at –80°C 
until analysis. Before analysis, samples were 
diluted 1:5 with water–methanol to bring the 
methanol concentration to 2.5%, incubated 
at 5°C to precipitate poorly soluble material, 
and filtered (0.45 μm). Analysis was performed 
by HPLC­ICP­MS (Agilent 1090 HPLC and 
Agilent 7500CE ICP­MS run in normal mode; 
both from Agilent Technologies, Santa Clara, 
CA) under conditions that resolved neutral, 
tri  valent, and penta  valent iAs species. The ion­
pairing method (Le et al. 2000) was used with 
major modifications to improve the resolution 
of the species. Briefly, calibrants were prepared 
from neat materials [As2O3 (Aldrich) and 
As2O5 (Acros), Sigma­Aldrich; DMAV and 
MMAV · 6H2O, Chem Service, West Chester, 
PA] in deionized water (≥ 18 MΩ). For spe­
ciation, we used a Phenomenex Gemini­NX 
column (3 μm, C18, 110Å, 150 × 4.6 mm; 
Torrance, CA) with a corresponding guard 
column at 40°C. Concentrations of arsenic 
species in stock solutions were standardized 
against NIST traceable commercial ICP­MS 
standards (VWR BDH Aristar Plus; Ultra 
Scientific, Kingstown, RI). Serial dilutions 
were made into deionized water. iAsIII and 
iAsV species were quantified by separate cali­
brant series, and iAsIII concentration in the  N6AMT1 methylates MMAIII
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calibrants was corrected for any conversion 
to iAsV. The HPLC conditions were isocratic 
(5 mM tetrabutyl  ammonium hydroxide, 
10 mM ammonium carbonate, 2.5% metha­
nol, pH 9.2, 1 mL/min) for 5 min; then a 
step gradient (5 mM tetra  butyl  ammonium 
hydroxide, 30 mM ammonium carbonate, 
2.5% methanol, pH 8.75, 1.2 mL/min) for 
5 min to elute iAsV was followed by step gradi­
ents (5 mM tetra  butyl  ammonium hydroxide, 
30 mM ammonium carbonate, 2.5% metha­
nol, pH 9.2, 1.2 mL/min) for a 5­min equil­
ibration to the initial pH and finally to the 
initial mobile phase for 5 min (1.2 mL/min). 
The data were analyzed by LC ChemStation 
A.09.03 and ICP­MS ChemStation B.03.03 
software (Agilent Technologies). 
Data analysis. Statistical analyses were 
performed using one­way analysis of variance. 
Data represent mean ± SE of at least three 
independent experiments. 
Results
Deletion of yeast MTQ2 leads to increased 
resistance to arsenic treatment. We evaluated 
the growth pheno  type of the MTQ2­deletion 
mutants in the presence of either iAsIII or 
MMAIII (Figure 1). Deletion strains and their 
iso  genic wild­type counter  part, BY4743, 
were treated with equi  oxic doses equivalent 
to the concentrations that resulted in 20% 
growth inhibition (IC20) and 2 × IC20, which 
were 300 and 600 μM for iAsIII and 150 and 
300 μM for MMAIII, respectively. iAsIII treat­
ments had no effect on the growth of MTQ2­
deletion mutants but significantly decreased 
growth of the wild­type strain. In compari­
son, the growth of both MTQ2­deletion 
mutants and wild­type yeast treated with 
MMAIII decreased to the same degree despite 
the higher toxicity of MMAIII.
Differential level of N6AMT1 mRNA 
expression in human tissues. A direct search 
for sequence homology and conserved func­
tional domains revealed that the human 
N6AMT1 gene is orthologous to the yeast 
MTQ2 gene. We used the web­based online 
tool Protein Function Prediction (PFP; 
Kihara Bioinformatics Laboratory 2010), 
to analyze and predict its potential func­
tions (Hawkins et al. 2009). The suggested 
molecular functions of N6AMT1 include 
protein hetero  dimerization and methio­
nine S­methyltransferase activity, with 
an almost certain (100%) predicted prob­
ability of being a methyl  transferase. Given 
N6AMT1’s suggested function as a methyl­
transferase, we were interested in exploring 
its potential involve  ment in arsenic biom­
ethylation. Considering that the primary 
methyl  transferase responsible for arsenic 
metabo  lism in human cells is AS3MT, we did 
pairwise alignment analysis of N6AMT1 and 
AS3MT using EMBOSS Pairwise Alignment 
Algorithms, an online tool (European 
Bioinformatics Institute 2010). The two 
proteins shared about 25% similarity. Of the 
three sequence motifs found in most AS3MT 
homologs, only motif ILDLGSGSG is highly 
conserved in N6AMT1 [LEVGSGSG; see 
Supplemental Material, Figure 1(doi:10.1289/
ehp.1002733)], whereas (D/N)PPY is pres­
ent in N6AMT1 but not in AS3MT. These 
differences suggest that the mechanism by 
which N6AMT1 methylates arsenic may dif­
fer from that of AS3MT, if N6AMT1 is, in 
fact, involved in the methylation of arsenicals.
A search of the Expressed Sequence 
Tags (EST) Database (National Center for 
Biotechnology Information 2010) revealed 
sequences matching the cDNA of N6AMT1 
in many human tissues with varied expres­
sion levels. To experimentally measure the 
mRNA expression of N6AMT1 across tissues, 
we performed rt­qPCR analysis using cDNA 
from a panel of 48 human tissues contained 
in a tissue array (Figure 2). We confirmed 
the amplification products to be N6AMT1 by 
DNA sequencing. Using the liver as a refer­
ence, the expression of N6AMT1 was normal­
ized to the expression level of ACTB [with 
cycle threshold (Ct) values ranging from 
18 to 20] and found to be relatively highly 
expressed in tissues such as the parathyroid, 
pituitary, adrenal gland, and kidney, and 
weakly expressed in tissues such as the skin, 
lung, and mammary gland. We also meas­
ured AS3MT mRNA levels using the same 
tissue panel in order to compare N6AMT1 
Figure 1. Deletion of the MTQ2 gene in yeast results in increased resistance to arsenite (iAsIII), shown as the growth phenotype of MTQ2 mutant yeast cells (B) 
and the wild-type BY4743 cells (A) treated with 300 or 600 μM iAsIII or 150 or 300 μM MMAIII. Growth curves show the OD595 for each treatment as a function of 
time for 24 hr. Bars represent the mean ± SE AUC for three technical replicates. At the doses tested, iAsIII treatment did not alter the growth pattern of MTQ2 
mutants but led to a dose-dependent reduction in growth of the wild-type strain; the growth patterns of both yeast strains were similar after MMAIII exposure.
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expression in each tissue and AS3MT expres­
sion [see Supplemental Material, Figure 2 
(doi:10.1289/ehp.1002733)]. The data 
showed that the level of N6AMT1 mRNA 
was relatively low in most meas  ured tissues 
compared with AS3MT mRNA. The presence 
of detectable levels of N6AMT1 expression in 
all tissues analyzed suggests that this enzyme 
could be involved in methylating arsenicals. 
N6AMT1 may act in parallel to AS3MT and 
may be functional only under certain condi­
tions or in certain tissues.
Figure 2. N6AMT1 mRNA expression in human tissues, quantified by rt-qPCR analysis a panel of 48 normal human tissues; transcript levels of N6AMT1 were nor-
malized to ACTB expression and are shown as the fold change relative to liver. 
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Figure 3. Enhancing expression of human N6AMT1 in UROtsa cells increases resistance to both iAsIII and MMAIII treatment. (A) Representative images of UROtsa 
cells with either plasmid alone or plasmid with N6AMT1; bars = 10 μm. (B) Semiquantitative RT-PCR analysis shows dramatically increased N6AMT1 expression 
in UROtsa cells with N6AMT1 relative to control cells or cells with plasmid. AS3MT mRNA was not detected in either cell line; ACTB was used as the loading 
control. UROtsa cells with vector and with N6AMT1 were treated with increasing concentrations of iAsIII (C) or MMAIII (D) for 24 hr, and cell viability was evalu-
ated with MTT. Bars represent the mean ± SD of three independent experiments. Treatment with either iAsIII or MMAIII resulted in a dose-dependent decrease in 
viability. However, increased expression of N6AMT1 in UROtsa cells led to resistance to both iAsIII (C) and MMAIII (D); this effect was more significant when cells 
were treated with MMAIII than with iAsIII. 
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Overexpression of N6AMT1 in UROtsa 
cells increases resistance to arsenic treatment. 
We also measured and compared the level of 
N6AMT1 mRNA in several cell lines, includ­
ing 293 (human embryonic kidney cells), 
HeLa, UROtsa, and HL60 (human pro­
myeloc  ytic leukemia cells). N6AMT1 expres­
sion in UROtsa cells is relatively low, with a 
Ct value of about 33 (data not shown). This 
cell line also has almost no detectable level 
of AS3MT, making it an excellent model to 
study the role of N6AMT1 in arsenic toxicity 
and metabolism in mammals. We enhanced 
N6AMT1 expression in UROtsa cells using a 
retrovirus­based vector (Figure 3A) and found 
the level of N6AMT1 mRNA in UROtsa cells 
to be significantly increased by approximately 
5­fold in clone 2, as measured by semiquan­
titative RT­PCR (Figure 3B). We also meas­
ured AS3MT gene expression in these two cell 
lines and found no detectable mRNA level in 
either cell line (Figure 3B). We further con­
firmed these PCR results by real­time PCR 
analysis (data not shown). Unfortunately, we 
could not detect N6AMT1 protein levels in 
these cells using two commercially available 
anti  bodies. Transfected UROtsa cells did not 
have an altered doubling time or morphology 
in culture. The UROtsa cells with N6AMT1 
(N6AMT1­enhanced cells) and the UROtsa 
cells with vector cells (vector control) were 
treated with either iAsIII or MMAIII at a series 
of concentrations for 24 hr. Arsenical treat­
ments induced a dose­dependent decrease in 
viability of both cell lines. However, increased 
expression of N6AMT1 in UROtsa cells 
resulted in higher viability after iAsIII and 
MMAIII treatment at almost all concentra­
tions tested, compared with the UROtsa vec­
tor control cells (Figure 3C,D). This increased 
arsenic resistance was more apparent in cul­
tures treated with MMAIII than with iAsIII, 
approximately 2­ and 1.3­fold, respectively.
Enhanced N6AMT1 in UROtsa cells 
  methylates MMAIII to DMA. We collected 
medium and cell extracts from cultures of 
UROtsa cells with N6AMT1 and UROtsa cells 
with vector treated with different concentra­
tions of either iAsIII or MMAIII for up to 3 days 
and then meas  ured and analyzed arsenic meta­
bolic profiles using ICP­MS [for representative 
chromatograms, see Supplemental Material, 
Figure 3 (doi:10.1289/ehp.1002733)]. 
Methylated metabolites were undetectable 
either in the media (Table 1) or in the cell 
extract (Table 2) from cultures of UROtsa 
cells with N6AMT1 or of UROtsa cells with 
vector, after treatment of with iAsIII, suggest­
ing that N6AMT1 does not methylate iAsIII. 
When UROtsa cells with vector control were 
treated with MMAIII, levels of MMAV but 
not dimethylarsinic acid (DMAV) increased 
in the media (Table 3) and cells (Table 2). 
Treatment with MMAIII of UROtsa cells with 
N6AMT1 resulted in similarly increased levels 
of MMAV andled to increased levels of DMAV 
in the media after 24 and 72 hr (Table 3) 
and, to a lesser degree, in the cell extracts 
after 72 hr (Table 2). At 24 hr, the level of 
DMAV was similar at each dose level, but after 
3 days treatment levels in both media and cell 
extract increased in relation to the initial con­
centration of MMAIII, in a dose­dependent   
manner. Moreover, the amount of DMAV 
in the culture medium increased 5­fold after 
3 days of treatment (1 μM MMAIII) compared 
with 1 day of treatment.
Discussion
MMAIII is the most toxic arsenic metabo-
lite in vivo and in vitro. In humans, iAs is 
metabo  lized to methylated arsenical species 
in a multi  step process. Methylated arsenicals, 
especially MMAIII, may be more toxic than 
iAs both in vivo and in vitro (Drobná et al. 
2005; Ferrario et al. 2008; Kligerman et al. 
2003; Petrick et al. 2001). In cultured human 
cells, MMAIII is the most toxic arsenical 
(Drobná et al. 2005; Ferrario et al. 2008; 
Petrick et al. 2001) and inhibits several key 
cellular proteins, such as glutathione reductase 
(Styblo et al. 1997) and thio  redoxin reductase 
(Lin et al. 1999, 2001). Several studies have 
shown that MMAIII is capable of inducing 
genetic damage and changes in signal trans­
duction by either direct or indirect mecha­
nisms (Ahmad et al. 2002; Kligerman et al. 
2003; Nesnow et al. 2002). In addition, 
exposure to MMAIII for 52 weeks induced 
malignant transformation of UROtsa cells 
(Bredfeldt et al. 2006). Epidemiological 
studies have suggested that individuals who 
Table 1. Arsenic metabolic profile in cell culture medium after iAsIII treatment of UROtsa cells with vector 
and UROtsa cells with N6AMT1 (ng/mL; mean ± SE).
iAsIII (μM)
UROtsa cells with vector UROtsa cells with N6AMT1
iAs(III +V) MMAIII MMAV DMAV iAs(III +V) MMAIII MMAV DMAV
1 day
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
1 261.50 ± 126.22 BLOQ BLOQ BLOQ 417.00 ± 1.41 BLOQ BLOQ BLOQ
3 1109.00 ± 11.31 BLOQ BLOQ BLOQ 1159.00 ± 12.02 BLOQ BLOQ BLOQ
10 3695.50 ± 10.96 BLOQ BLOQ BLOQ 3751.00 ± 72.12 BLOQ BLOQ BLOQ
3 days
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
1 425.50 ± 8.13 BLOQ BLOQ BLOQ 414.50 ± 5.30 BLOQ BLOQ BLOQ
3 1034.00 ± 2.12 BLOQ BLOQ BLOQ 1017.00 ± 7.07 BLOQ BLOQ BLOQ
BLOQ, below the limit of quantitation (the m/z 75 signal at the retention time of the species is not distinguishable from the 
baseline signal). 
Table 3. Arsenic metabolic profile in cell culture medium after MMAIII treatment of UROtsa cells with 
vector and UROtsa cells with N6AMT1 (ng/mL; mean ± SE).
MMAIII (μM)
UROtsa cells with vector UROtsa cells with N6AMT1
iAs(III+V) MMAIII MMAV DMAV iAs(III+V) MMAIII MMAV DMAV
Treated 1 day
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
0.5 BLOQ Present 112.00 ± 0.71 BLOQ BLOQ Present 104.00 ± 0.71 21.50 ± 0.35
1 BLOQ Present 236.50 ± 15.20 BLOQ BLOQ Present 210.00 ± 2.12 22.50 ± 1.06
2 BLOQ Present 468.00 ± 17.68 BLOQ BLOQ Present 424.50 ± 6.72 20.00 ± 0.71
Treated 3 days
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
0.5 BLOQ Present 115.00 ± 2.12 BLOQ BLOQ Present 106.00 ± 2.83 72.00 ± 4.24
1 BLOQ Present 277.00 ± 5.66 BLOQ BLOQ Present 236.50 ± 9.55 105.50 ± 4.60
BLOQ, below the limit of quantitation (the m/z 75 signal at the retention time of the species is not distinguishable from 
the baseline signal). “Present” indicates that the peak was seen at MMAIII retention time; no concentration is given 
because the samples were not analyzed by the MMAIII assay. 
Table 2. Arsenic metabolic profile in cell extract after 3-day iAsIII and MMAIII treatment of UROtsa cells 
with vector and UROtsa cells with N6AMT1 (ng/mL; mean ± SE).
Treatment (μM)
UROtsa cells with vector UROtsa cells with N6AMT1
iAs(III+V) MMAIII MMAV DMAV iAs(III+V) MMAIII MMAV DMAV
iAsIII
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
1 2.7 ± 0.3 BLOQ BLOQ BLOQ 5.7 ± 0.6 BLOQ BLOQ BLOQ
3 12.0 ± 2.0 BLOQ BLOQ BLOQ 14.5 ± 0.5 BLOQ BLOQ BLOQ
MMAIII
0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ
0.5 BLOQ BLOQ 3.5 ± 0.7 BLOQ BLOQ BLOQ 3.0 ± 0.1 2.8 ± 0.2
1 BLOQ BLOQ 2.9 ± 0.8 BLOQ BLOQ BLOQ 4.7 ± 0.0 4.8 ± 0.6
BLOQ, below the limit of quantitation (the m/z 75 signal at the retention time of the species is not distinguishable from the 
baseline signal). Ren et al.
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excrete a higher proportion of ingested 
arsenic as MMAIII are more susceptible to 
arsenic­  related cancer (Steinmaus et al. 2006). 
MMAIII has been proposed as the ultimate 
geno  toxic form of arsenic (Kligerman et al. 
2003), and the existing evidence indicates 
that biomethylation of iAs to MMAIII is likely 
to alter the adverse effects of environmental 
arsenic exposure on human health.
AS3MT is primarily responsible for 
  methylating iAs to MMAIII and DMA in 
humans. The arsenic methyltransferase 
AS3MT is recog  nized as the primary enzyme 
responsible for conversion of iAs to its methy­
lated metabolites MMAIII and DMA (Lin 
et al. 2002; Wood et al. 2006). Studies have 
shown that single­nucleotide poly  morphisms 
in AS3MT lead to different urinary arseni­
cal profiles (Agusa et al. 2009; Schläwicke 
Engström et al. 2009; Wood et al. 2006), 
some of which are associated with increased 
risk of pre  malignant skin lesions (Valenzuela 
et al. 2009). Although these data suggest 
that AS3MT plays a critical role in arsenic 
methyla  tion and toxicity, a recent study 
showed that As3mt­knockout mice retain 
some ability to methylate arsenicals, suggest­
ing the existence of other methyl  transferases 
that could be involved in alternative arsenic 
metabolism pathways (Drobna et al. 2009).
N6AMT1 is capable of methylating 
MMAIII to DMA. In this study, we found 
that N6AMT1 has the capacity to methylate 
MMAIII to DMA. The expression of N6AMT1 
is generally low compared with the expression 
level of AS3MT in most human tissues. In 
addition, the low sequence homology shared 
between these two proteins, about 25%, sup­
ports differences in substrate specificity and, 
possibly, in mechanisms of arsenic methyla­
tion. In contrast to AS3MT, which methy­
lates iAs to the more toxic MMAIII, N6AMT1 
methylates MMAIII to the less toxic DMA. 
This is consistent with the increased resistance 
to MMAIII of UROtsa cells over  expressing 
N6AMT1 compared with vector control 
cells, but other mechanisms likely also con­
tribute to this increased resistance. Thus, our 
results suggest that N6AMT1 may play a role 
in modulating arsenical­induced toxicity and 
that decreased N6AMT1 expression or activity 
could have a significant impact on arsenic­
induced toxicity and perhaps carcinogenicity 
under certain conditions or in certain tissues.
N6AMT1 in human cells responded to 
arsenicals differently from MTQ2 in yeast. 
We noted differences in response to arseni­
cal treatments between yeast and human cells. 
Specifically, the MTQ2­deletion yeast strain 
is resistant only to iAsIII. We did not find evi­
dence of iAsIII methylation in yeast wild­type; 
that is, DMA and MMA levels in cells and cul­
ture media were below the limit of quantitation 
(data not shown). Therefore, the function of 
MTQ2 in arsenic toxicity may not be related to 
iAsIII methylation. In contrast, over  expression 
of N6AMT1 in UROtsa cells leads to resis­
tance to both iAsIII and MMAIII, which pro­
vides evidence of its involvement in protection 
from these arsenicals. These results indicate 
that the orthologous genes—MTQ2 in yeast 
and N6AMT1 in humans—have different roles 
in the cellular response to arsenic toxicity.
Conversion of MMAIII to DMA by 
N6AMT1 needs to be further confirmed 
biochemically. Our analyses showed that 
enhanced expression of N6AMT1 in UROtsa 
cells converts MMA to DMA. However, puri­
fied recombinant N6AMT1, in the presence 
of SAM and other cofactors, was unable to 
methylate iAsIII or MMAIII (data not shown). 
N6AMT1 dimerizes with tRNA methyl­
transferase 11­2 homolog (TRMT112), which 
appears to be necessary for proper N6AMT1 
function (Figaro et al. 2008) and is consistent 
with hetero  dimerization activity as predicted 
with PFP. Thus, the lack of N6AMT1­
dependent MMAIII methylation in this test 
tube experiment may be due to the absence of 
TRMT112 or another unknown protein. In 
addition, N6AMT1 over  expression increased 
resistance to iAsIII, although UROtsa cells 
were not able to methylate iAsIII to MMAIII 
or to other methylated species, suggesting that 
mechanisms other than participation in arsenic 
methylation might be involved. It is not clear 
whether inter  action between N6AMT1 and 
TRMT112 has a role in arsenic toxicity, but it 
is certainly worthy of further investigation.
Conclusions
Our data suggest an important potential role 
of N6AMT1 in modulating arsenical­induced 
toxicity by methylating MMAIII to the less 
toxic DMA. However, further investigation 
is warranted to determine whether N6AMT1 
can methylate MMAIII in vivo and also to 
identify the genetic and environmental factors 
that can alter N6AMT1 expression and/or   
activity. Our ongoing experiments are focused 
on the biochemical characterization of 
N6AMT1, specifically its capacity to meth  yl­
ate MMAIII, as well as its ability to modulate 
arsenic toxicity and carcinogenicity.
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